Jump to main content.

2,2',4,4',5-Pentabromodiphenyl ether (BDE-99) Quickview (CASRN 60348-60-9)

Health assessment information on a chemical substance is included in IRIS only after a comprehensive review of toxicity data by U.S. EPA health scientists from several Program Offices, Regional Offices, and the Office of Research and Development.

Disclaimer: This QuickView represents a snapshot of key information. We suggest that you read the IRIS Summary to put this information into complete context.

For definitions of terms in the IRIS Web site, refer to the IRIS Glossary.

Status of Data for 2,2',4,4',5-Pentabromodiphenyl ether (BDE-99)

File First On-Line: 06/30/2008; Last Significant Revision: 06/30/2008

Category (section)
Last Revised
Oral RfD Assessment Yes 06/30/2008
Inhalation RfC Assessment Discussion 06/30/2008
Carcinogenicity Assessment Yes 06/30/2008
  • Benzene, 1,2,4,-tribromo-5-(2,4-dibromophenoxy)-
  • BDE-99
  • Diphenyl ether, pentabromo
  • PBDE 99
  • 60348-60-9
  • 2,2',4,4',5-Pentabromodiphenyl ether
Revision History
Date Section Description
06/30/2008 I., II. RfD, RfC, and cancer assessment first on line.
Chronic Health Hazard Assessments for Noncarcinogenic Effects

Reference Dose for Chronic Oral Exposure (RfD)

Critical Effect
Point of Departure*
Neurobehavioral effects BMDL (1SD): 0.29 mg/kg 3000 1 x10-4 mg/kg-day

* The Point of Departure listed serves as a basis from which the Oral RfD was derived. See Discussion of Conversion Factors and Assumptions for more details.

Top of page

Reference Concentration for Chronic Inhalation Exposure (RfC)

Information reviewed but value not estimated. See IRIS Summary.

Top of page

Carcinogenicity Assessment for Lifetime Exposure
  • Weight-of-Evidence Characterization
    • Inadequate information to assess carcinogenic potential
  • Weight-of-Evidence Narrative:
    • Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), there is "inadequate information to assess the carcinogenic potential" of 2,2',4,4',5-pentabromodiphenyl ether (BDE-99).
    • This may be a synopsis of the full weight-of-evidence narrative. See IRIS Summary.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure

  • Not Assessed under the IRIS Program.

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure

  • Not Assessed under the IRIS Program.

Top of page

Recent Additions | Advanced Search | IRIS Home | Environmental Assessment | Research

Local Navigation

Jump to main content.